Market News

Gemphire Therapeutics Inc. (GEMP) Reaches $6.53 After 9.00% Down Move; Atika Capital Management Has Trimmed By $2.17 Million Its Arista Networks (ANET) Position

Arista Networks, Inc. (NYSE:ANET) Logo

Atika Capital Management Llc decreased Arista Networks Inc (ANET) stake by 25.76% reported in 2018Q1 SEC filing. Atika Capital Management Llc sold 8,500 shares as Arista Networks Inc (ANET)’s stock declined 1.58%. The Atika Capital Management Llc holds 24,500 shares with $6.25M value, down from 33,000 last quarter. Arista Networks Inc now has $20.91 billion valuation. The stock decreased 0.93% or $2.63 during the last trading session, reaching $281.11. About 257,179 shares traded. Arista Networks, Inc. (NYSE:ANET) has risen 72.73% since June 21, 2017 and is uptrending. It has outperformed by 60.16% the S&P500. Some Historical ANET News: 03/05/2018 – Arista Networks 1Q EPS $1.79; 13/04/2018 – Tech Today: Arista Cut, Defending Facebook, Amazon’s Postal Math — Barron’s Blog; 28/03/2018 – ARISTA: ITC ALJ SUPPORTS SUSPENSION OF REMEDIES ON CISCO PATENT; 28/03/2018 – ARISTA NETWORKS INC – ITC ISSUED RD IN ITC 945 MODIFICATION PROCEEDING INITIATED BY CISCO SYSTEMS, AGAINST ARISTA NETWORKS; 03/05/2018 – Arista Networks 1Q Net $144.5M; 22/04/2018 – DJ Arista Networks Inc, Inst Holders, 1Q 2018 (ANET); 11/04/2018 – Arista Networks Joins Fortinet Fabric-Ready Partner Program to Advance Security Automation Across Data Center and Cloud Networks; 19/03/2018 Tech Today: Bad Facebook, Oracle On Tap, Buying II-VI, Selling Arista — Barron’s Blog; 11/05/2018 – Arista Takes Aim at Cisco — Barrons.com; 10/05/2018 – Tech Today: Apple at $1 Trillion Soon, IAC Surges, Cheers for Arista — Barron’s Blog

The stock of Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a huge mover today! The stock decreased 9.05% or $0.65 during the last trading session, reaching $6.53. About 165,426 shares traded or 44.39% up from the average. Gemphire Therapeutics Inc. (NASDAQ:GEMP) has declined 37.19% since June 21, 2017 and is downtrending. It has underperformed by 49.76% the S&P500. Some Historical GEMP News: 18/05/2018 – Gemphire Therapeutics Provides the American Liver Foundation an Educational Grant in Support of Disease State Awareness for Pediatric NAFLD; 03/05/2018 – GEMPHIRE THERAPEUTICS INC – GULLANS HAS BEEN INTERIM PRESIDENT AND CHIEF EXECUTIVE OFFICER SINCE MAY 2017; 08/05/2018 – Gemphire Therapeutics 1Q Loss/Shr 58c; 18/05/2018 – Gemphire Therapeutics Provides the American Liver Foundation an Educational Grant in Support of Disease State Awareness for Ped; 12/04/2018 – Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4); 15/05/2018 – Adage Capital Partners GP LLC Exits Gemphire Therapeutics; 10/05/2018 – Sphera Funds Buys New 3.4% Position in Gemphire Therapeutics; 03/05/2018 – Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as Pres and CEO; 03/05/2018 – Gemphire Therapeutics: Gullans Has Been Interim CEO Since 2017; 19/03/2018 – Gemphire Therapeutics at Investor Day Hosted By H.C. WainwrightThe move comes after 7 months negative chart setup for the $92.94 million company. It was reported on Jun, 21 by Barchart.com. We have $5.94 PT which if reached, will make NASDAQ:GEMP worth $8.36M less.

Another recent and important Gemphire Therapeutics Inc. (NASDAQ:GEMP) news was published by Benzinga.com which published an article titled: “42 Biggest Movers From Yesterday” on June 13, 2018.

Analysts await Gemphire Therapeutics Inc. (NASDAQ:GEMP) to report earnings on August, 13. They expect $-0.57 earnings per share, up 22.97% or $0.17 from last year’s $-0.74 per share. After $-0.58 actual earnings per share reported by Gemphire Therapeutics Inc. for the previous quarter, Wall Street now forecasts -1.72% EPS growth.

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia cardiovascular disease and nonalcoholic fatty liver disease/non-alcoholic steatohepatitis . The company has market cap of $92.94 million. It is developing gemcabene (CI-1027), an oral therapy for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statin therapy and for those patients who present with NASH. It currently has negative earnings.

Among 3 analysts covering Gemphire Therapeutics (NASDAQ:GEMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Gemphire Therapeutics had 3 analyst reports since August 30, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, August 30 by Canaccord Genuity. RBC Capital Markets initiated it with “Outperform” rating and $25 target in Tuesday, August 30 report. Jefferies initiated it with “Buy” rating and $15 target in Tuesday, August 30 report.

More notable recent Arista Networks, Inc. (NYSE:ANET) news were published by: Fool.com which released: “Arista Networks Has a Shiny New Toy” on June 20, 2018, also Investorplace.com with their article: “Smart Plays in 2 Large-Cap Tech Stocks” published on June 19, 2018, Businesswire.com published: “Arista Announces New Multi-function Platform for Cloud Networking” on June 05, 2018. More interesting news about Arista Networks, Inc. (NYSE:ANET) were released by: Streetinsider.com and their article: “Nomura Warms To Arista Networks (ANET) After A HQ Visit” published on June 12, 2018 as well as Nasdaq.com‘s news article titled: “Research Report Identifies Aetna, Square, Overstock, INTL FCStone, Arista Networks, and Hanesbrands with Renewed …” with publication date: June 11, 2018.

Among 36 analysts covering Arista Networks (NYSE:ANET), 18 have Buy rating, 1 Sell and 17 Hold. Therefore 50% are positive. Arista Networks had 138 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Friday, February 16 by Gabelli. The company was maintained on Tuesday, February 20 by Nomura. As per Thursday, December 21, the company rating was maintained by Morgan Stanley. The firm earned “Sector Perform” rating on Wednesday, August 31 by RBC Capital Markets. On Friday, June 2 the stock rating was maintained by Oppenheimer with “Buy”. Bank of America upgraded the shares of ANET in report on Tuesday, November 22 to “Neutral” rating. The company was initiated on Thursday, August 18 by BMO Capital Markets. Stifel Nicolaus maintained Arista Networks, Inc. (NYSE:ANET) on Thursday, July 20 with “Hold” rating. Needham maintained Arista Networks, Inc. (NYSE:ANET) rating on Thursday, March 1. Needham has “Buy” rating and $315.0 target. On Friday, August 26 the stock rating was maintained by Citigroup with “Neutral”.

Atika Capital Management Llc increased Facebook Inc (NASDAQ:FB) stake by 7,000 shares to 52,000 valued at $8.31M in 2018Q1. It also upped Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) stake by 16,000 shares and now owns 41,000 shares. Advansix Inc was raised too.

Arista Networks, Inc. (NYSE:ANET) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *